Anthem Biosciences Limited – Investor Presentation Summary

Key Operational Highlights

  • Consolidated Revenue from Operations was ₹4,182 Mn for the quarter ended June 30, 2026 (Q1FY27).
  • CRDMO business delivered ₹3,408 Mn revenues.
  • Specialty Ingredients delivered ₹774 Mn revenues.
  • Net Cash position as of June 30, 2026 is ₹17,197 Mn.

Key drivers of operational performance: Timing shifts in deliveries to key customers, with higher concentration of scheduled deliveries expected in the latter half of the year.

Segment-wise Performance

  • CRDMO Business: Revenue of ₹3,408 Mn, representing -24.7% YoY growth from Q1FY26 (₹4,527 Mn) and -33.5% QoQ from Q4FY26 (₹5,128 Mn).
  • Specialty Ingredients: Revenue of ₹774 Mn, representing -11.5% YoY growth from Q1FY26 (₹875 Mn) and -21.1% QoQ from Q4FY26 (₹981 Mn).

Explanation of significant changes in segment performance: Both segments experienced revenue decline attributed to timing shifts in customer deliveries.

Financial Highlights

Revenue: ₹4,182 Mn

EBITDA: ₹1,755 Mn

PAT: ₹1,199 Mn

Margins: EBITDA Margin: 39.6%, PAT Margin: 27.1%

YoY/QoQ comparison: Revenue decreased 22.6% YoY from Q1FY26 (₹5,402 Mn) and 31.5% QoQ from Q4FY26 (₹6,109 Mn). EBITDA decreased 18.1% YoY from Q1FY26 (₹2,143 Mn) and 44.9% QoQ from Q4FY26 (₹3,184 Mn). PAT decreased 11.7% YoY from Q1FY26 (₹1,358 Mn) and 36.8% QoQ from Q4FY26 (₹1,898 Mn).

Drivers of financial performance: Year-on-year improvement across both EBITDA and PAT margins due to disciplined focus on cost efficiencies, yield optimisation, and employee productivity.

Comparison to market estimates: Not Specified

Key Risks: Not Specified

Geographical Revenue Split

Domestic vs Export/Regional Revenue: Not Specified

Regional Breakdown: Not Specified

Balance Sheet Snapshot

Net Debt/Equity: Not Specified

Reserves: Not Specified

Current Assets/Liabilities: Not Specified

Working Capital/Leverage Metrics: Not Specified

Financial Health Insights: Strong net cash position of ₹17,197 Mn as of June 30, 2026.

Capex & Cash Flow Health

Capital Expenditure: Not Specified

Free Cash Flow: Not Specified

Operating Cash Flow: Not Specified

Net Debt Movement: Not Specified

Investment Rationale: Not Specified

Strategic & R&D Initiatives

Investments in Innovation: Not Specified

Expected impact on growth: Not Specified

Strategic Rationale: Not Specified

Industry Trends & Business Environment

Macro/Industry Trends: Not Specified

Impact on Company: Not Specified

Management Commentary & Growth Outlook

Strategic Outlook: "Our Q1FY27 quarterly results reflect timing shifts in deliveries to key customers. The underlying demand remains strong, and with a higher concentration of scheduled deliveries in the latter half of the year, we are positioned to capture that momentum. We remain firmly committed to sustaining revenue growth aligned with our long-term historical performance."

FY Guidance: Not Specified

Market Share Targets: Not Specified

Risks and Opportunities: Not Specified